secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001551152-26-000002
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie cuts Q4 2025 adjusted EPS guidance by $0.71 on $1.265B IPR&D charge
--------------------------------------------------------------------------

- Q4 2025 adjusted EPS guidance revised to $2.61-$2.65 from prior $3.32-$3.36.
- Full-year 2025 adjusted EPS guidance lowered to $9.90-$9.94 from $10.61-$10.65.
- Pre-tax acquired IPR&D and milestones expense of $1,265M (unfavorable $0.71 to GAAP and adjusted EPS).
- Q4 2025 results not finalized; expense relates to collaborations and licensing deals.
- AbbVie does not forecast IPR&D/milestones expense due to uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000002/0001551152-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000002/abbv-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001551152-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer